Emergent BioSolutions Inc. 8-K

What Happened
Emergent BioSolutions (EBS) announced on April 16, 2026 that it entered into a new Credit Agreement providing a $150 million Initial Term Loan (drawn in full on the closing date) and a $75 million Delayed Draw Term Loan available for 24 months subject to conditions. The company also executed an amendment to its asset‑based lending (ABL) facility, reducing the revolving commitment from $100 million to $50 million and extending the revolver maturity to April 16, 2031. EBS used the new term loan proceeds plus cash on hand to repay and terminate its prior credit agreement dated August 30, 2024.

Key Details

• Initial Term Loan: $150.0 million drawn April 16, 2026; Delayed draw: $75.0 million available for 24 months (subject to covenants, including a consolidated secured leverage ratio ≤ 1.75:1.00).
• Interest and fees: Term SOFR (floor 3.00%) + 6.25% per annum (so minimum ~9.25%); default interest = +5.00% on overdue amounts; 1.00% p.a. fee on undrawn delayed draw during availability.
• Collateral & guarantees: Obligations guaranteed by material subsidiaries and secured by a first‑priority lien on Term Loan priority collateral and second‑priority lien on ABL priority collateral.
• Covenants & prepayments: Consolidated total leverage ratio capped at 5.25:1.00 (quarterly tests starting Sept. 30, 2026); mandatory prepayment rules for certain debt proceeds, asset sale proceeds above thresholds ($15M aggregate / $10M per transaction), and 50% of excess cash flow (with thresholds and step‑downs). Prepayment penalties apply (make‑whole + 3.0% in years 0–2, 3.0% in year 3, 2.0% in year 4).

Why It Matters
This financing provides immediate liquidity ($150M) and potential incremental capital ($75M delayed draw and an uncommitted incremental facility) to support operations, investments or capital expenditures. However, the new term loan carries a relatively high effective interest rate (SOFR floor plus 6.25%), is secured and guaranteed by subsidiaries, and includes covenant and prepayment terms that can limit flexibility and require use of cash for debt reduction in specified events. The ABL amendment reduces the available revolver capacity from $100M to $50M, which lowers the company’s near‑term undrawn backstop. Investors should note the changed debt profile, covenant tests beginning in late 2026, and potential for higher interest expense and restricted liquidity compared with prior arrangements.